Recent developments include CorMedix's Q1 2026 earnings report highlighting strong DefenCath sales momentum and raised guidance, ongoing clinical trials for expanded indications, and continued integration of the Melinta portfolio.

• CorMedix reported Q1 2026 earnings with strong DefenCath momentum and raised guidance, reflecting commercial progress [N4].
• The company held Q1 2026 earnings calls and released transcripts providing detailed operational and financial updates [N5][N6][N7].
• A Phase 3 clinical study for DefenCath in total parenteral nutrition patients is ongoing, targeting expanded indications [S1].
• CorMedix continues to integrate the Melinta acquisition, expanding its infectious disease and cardiovascular product portfolio [S1].

CorMedix benefits from a unique FDA-approved product, DefenCath, with demonstrated clinical efficacy in reducing serious infections in hemodialysis patients, supported by reimbursement pathways facilitating adoption. The acquisition of Melinta Therapeutics broadens the company's product offerings into infectious diseases and cardiovascular markets, providing cross-selling opportunities and diversification. Ongoing clinical trials for expanded indications and real-world evidence supporting DefenCath's value proposition may enhance market penetration. Strong liquidity and recent profitability provide financial flexibility to support growth initiatives.

CorMedix faces risks from reimbursement changes, including the transition from TDAPA to post-TDAPA adjustments, which may reduce net pricing for DefenCath. The company's reliance on a limited number of large customers creates revenue concentration risk, with potential for significant fluctuations. Dependence on third-party manufacturers, some single-source, exposes the company to supply chain disruptions and regulatory compliance risks. Integration challenges from the Melinta acquisition and uncertainties in clinical trial outcomes for expanded indications may impact future performance. Regulatory and competitive pressures in the pharmaceutical industry also pose ongoing challenges.

CorMedix's competitive advantage stems from DefenCath being the only FDA-approved antimicrobial catheter lock solution in the U.S., addressing a significant unmet medical need by reducing catheter-related bloodstream infections in hemodialysis patients. The product's demonstrated clinical efficacy and reimbursement designations support its market adoption. The acquisition of Melinta Therapeutics expanded CorMedix's commercial portfolio with established anti-infective products, enhancing its multi-channel hospital and clinic presence. The company's focus on expanding indications and leveraging synergies across its product portfolio further supports its market position. However, reliance on third-party manufacturing and customer concentration present operational risks.

• Reimbursement Risk: Changes in Medicare and other third-party payor reimbursement policies, including the transition from TDAPA to post-TDAPA add-on payments, may reduce net pricing and adversely affect revenues and profitability [S1].
• Customer Concentration: A significant portion of revenue is derived from a few large customers with no purchase commitments, creating risk of revenue volatility if purchasing patterns change [S1].
• Manufacturing and Supply Chain: Dependence on third-party contract manufacturers and suppliers, some single-source, exposes the company to risks of supply disruptions, regulatory non-compliance, and cost increases [S1].
• Regulatory and Clinical Development: The company faces risks related to obtaining and maintaining regulatory approvals, successful completion of clinical trials for expanded indications, and compliance with FDA requirements [S1].
• Integration and Operational Risks: Challenges related to integrating the Melinta acquisition, managing growth, and executing business strategy may impact operational efficiency and financial results [S1][S2].

• CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [S1].
• The company's primary commercial product is DefenCath®, an antimicrobial catheter lock solution (taurolidine and heparin) approved by the FDA to reduce catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC) [S1].
• DefenCath was launched commercially in April 2024 in inpatient settings and July 2024 in outpatient hemodialysis settings and is the largest contributor to the company's net sales [S1].
• CorMedix acquired Melinta Therapeutics, LLC in August 2025, expanding its commercial platform and portfolio to include six marketed infectious disease products and one cardiovascular product, collectively called the Melinta Portfolio [S1].
• The Melinta Portfolio products include REZZAYO® (rezafungin for injection), MINOCIN® (minocycline) for injection, VABOMERE® (meropenem and vaborbactam), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin), BAXDELA® (delafloxacin), and TOPROL-XL® (metoprolol succinate) [S1].
• The Melinta Portfolio targets serious gram-positive, gram-negative, and fungal infections in hospital and clinic settings, including emergency departments, outpatient clinics, and home infusion care, providing synergy opportunities with DefenCath [S1].
• DefenCath is the only FDA-approved antimicrobial catheter lock solution in the U.S. and was shown in a Phase 3 clinical study to reduce the risk of CRBSI by up to 71% [S1].
• A retrospective real-world evidence study reported a 70% reduction in annualized hospitalizations secondary to CRBSI when dialysis patient catheters are locked with DefenCath [S1].
• DefenCath has multi-year commercial supply agreements with dialysis organizations representing roughly 60% of outpatient dialysis centers in the U.S. by total addressable patient market [S1].
• The company is pursuing expanded indications for DefenCath, including reduction of central line associated bloodstream infection (CLABSI) in adult patients receiving total parenteral nutrition (TPN) via CVC, with a Phase 3 clinical study initiated in 2025 [S1].
• DefenCath has received various Medicare reimbursement designations, including New Technology Add-on Payment (NTAP) for inpatient use and Transitional Drug Add-on Payment Adjustment (TDAPA) for outpatient dialysis services, with TDAPA transitioning to a post-TDAPA add-on adjustment in July 2026 [S1].
• The company anticipates a reduction in net pricing for DefenCath in the second half of 2026 due to changes in reimbursement methodology [S1].
• REZZAYO is a once-weekly intravenous echinocandin approved in the U.S. in March 2023 for treatment of candidemia and invasive candidiasis in adults with limited or no alternative options [S1].
• CorMedix holds exclusive U.S. distribution and marketing rights for REZZAYO acquired through the Melinta acquisition, with rights to the NDA and sNDAs transferring from Mundipharma by June 30, 2028 or earlier upon marketing approval for prophylaxis indication [S1].
• The company is evaluating REZZAYO for prophylaxis of invasive fungal infections in immunocompromised adult patients undergoing allogeneic blood and marrow transplantation [S1].
• CorMedix outsources all manufacturing processes to third-party contract manufacturing organizations (CMOs), with FDA-approved suppliers for active pharmaceutical ingredients and finished dosage forms [S1].
• The company is engaged in technology transfers to reduce costs and onshore manufacturing over the next two to three years [S1].
• CorMedix has a contract with the Biomedical Advanced Research and Development Authority (BARDA) supporting pediatric use and biothreat pathogen studies for BAXDELA and VABOMERE, with reimbursement recognized to date [S1].
• As of June 30, 2026, CorMedix reported cash and equivalents of $256.7 million, current assets of $480.6 million, current liabilities of $187.4 million, a current ratio of 2.56, and a cash ratio of 1.43 [S2].
• For the fiscal year ended December 31, 2025, the company reported revenue of $311.7 million [S1].
• For the quarter ended June 30, 2026, CorMedix reported net income of $25.99 million, basic EPS of $0.33, and diluted EPS of $0.29 [S2].
• The company has significant customer concentration, with the top three customers accounting for 79% of total revenue in 2025, and no purchase commitments from these customers [S1].
• CorMedix employs approximately 191 full-time employees as of February 28, 2026, with offices in Parsippany, NJ, Lake Forest, IL, and remote locations [S1].
• The company faces risks related to reimbursement changes, manufacturing dependencies on third parties, customer concentration, and regulatory compliance [S1][S2].
• Recent news highlights include Q1 2026 earnings with strong DefenCath momentum and raised guidance, and ongoing clinical and commercial developments [N4][N5][N6][N7].